

Publications

1995

1. Benzing A., Bräutigam P., Geiger KK., **Loop T.**, Beyer U., Moser E.: Inhaled nitric oxide reduces pulmonary transvascular albumin flux in patients with acute lung injury. *Anesthesiology* 1995; 83:1153-1161 (IF: 3.501)

1996

2. Benzing A., **Loop T.**, Mols G., Geiger KK.: Effect of inhaled nitric oxide on venous admixture depends on cardiac output in patients with acute lung injury and acute respiratory distress syndrome. *Acta Anaesthesiol Scand* 1996;40:466-474 (IF: 1.68)

1999

3. Benzing A., **Loop T.**, Mols G., Geiger KK.: Unintended inhalation of nitric oxide by contamination of compressed air: physiologic effects and interference with intended nitric oxide inhalation in acute lung injury. *Anesthesiology* 1999; 91:945-950 (IF: 3.501)
4. Mols G., Brandes I., Kessler V., Lichtwarck-Aschoff M., **Loop T.**, Geiger K., Guttman J.: Volume-dependent compliance in ARDS: proposal of a new diagnostic concept. *Intensive Care Med* 1999; 25:1084-1091 (IF: 2.971)

2000

5. **Loop T.**, Priebe HJ.: Recovery after anesthesia with remifentanyl combined with propofol, desflurane, or sevoflurane for otorhinolaryngeal surgery. *Anesth Analg* 2000; 91:123-129 (IF: 2.210)
6. von der Esche U., Ayoub M., Pfannes SD., Mueller MR., Huber M., Wiesmueller KH., **Loop T.**, Humar M., Fischbach KF., Strunkelberg M., Hoffmann P., Bessler WG., Mittenbuehler K.: Immunostimulation by bacterial components: I. Activation of macrophages and enhancement of genetic immunization by the lipopeptide P3CSK4. *Int J Immunopharmacol* 2000; 22:1093-1102 (IF : 2.203)

2001

7. Hoetzel A., Vagts DA., **Loop T.**, Humar M., Bauer M., Pahl HL., Geiger KK., Pannen BHJ.: Effect of nitric oxide on shock-induced hepatic heme oxygenase-1 expression in the rat. *Hepatology* 2001; 33:925-937 (IF: 9.503)
8. Pannen BHJ., Schroll S., **Loop T.**, Bauer M., Hoetzel A., Geiger KK.: Hemorrhagic shock primes the hepatic portal circulation for the vasoconstrictive effects of endothelin-1. *Am J Physiol Heart Circ Physiol* 2001; 281:H1075-1084 (IF: 3.658)

2002

9. **Loop T.**, Liu Z., Humar M., Hoetzel A., Benzing A., Pahl HL., Geiger KK., Pannen BH.: Thiopental inhibits the activation of nuclear factor κ B. *Anesthesiology* 2002; 96:1202-1213 (IF: 3.501)
10. **Loop T.**, Priebe HJ.: A prospective, randomised cost analysis of anesthesia with remifentanyl combined with propofol, desflurane or sevoflurane for otorhinolaryngeal surgery. *Acta Anaesthesiol Scand* 2002; 46:1251-60 (IF: 1.680)
11. Mueller MR., Wiesmueller KH., Jung G., **Loop T.**, Humar M., Pfannes SD., Bessler WG., Mittenbuehler K.: Lipopeptide adjuvants: monitoring and comparison of P3CSK4- and LPS-induced gene transcription. *Int Immunopharmacol* 2002; 2:1065-1077 (IF : 2.203)

12. Hoetzel A., Geiger S., **Loop T.**, Welle A., Schmidt R., Pahl HL., Geiger KK., Pannen BHJ.: Differential effects of volatile anesthetics on hepatic heme oxygenase-1 expression in the rat. *Anesthesiology* 2002; 97:1318-21 (IF: 3.501)

2003

13. **Loop T.**, Humar M., Pischke S., Hoetzel A., Schmidt R., Pahl HL., Geiger KK., Pannen BHJ.: Thiopental inhibits tumor necrosis factor α -induced activation of nuclear factor κ B through suppression of κ B kinase activity. *Anesthesiology* 2003; 99:360-367 (IF:3.501)
14. Morse D., Pischke SE., Zhou Z., Davis RJ., Flavell RA., **Loop T.**, Otterbein SL., Otterbein LE., Choi AM.: Suppression of inflammatory cytokine production by carbon monoxide involves the c-Jun NH2 terminal kinase (JNK) pathway and activator protein-1 (AP-1). *J Biol Chem* 2003; 278:36993-36998 (IF: 6.482)

2004

15. Humar M., Pischke SE., **Loop T.**, Hoetzel A., Schmidt R., Klaas C., Pahl HL., Geiger KK., Pannen BH.: Barbiturates directly inhibit the calmodulin/calcineurin complex: a novel mechanism of inhibition of nuclear factor of activated T cells. *Mol Pharmacol* 2004; 65:350-361 (IF: 5.650)
16. Schmidt R., Hoetzel A., Baechle T., **Loop T.**, Humar M., Bauer M., Pahl H.L., Geiger K.K., Pannen B.H.J.: Isoflurane pretreatment lowers portal venous resistance by increasing hepatic heme oxygenase activity in the rat liver in vivo. *J Hepatol* 2004; 41:706-713 (IF: 5.283)
17. Humar M., Andriopoulos N., Pischke SE., **Loop T.**, Schmidt R., Hoetzel A., Roesslein M., Pahl HL., Geiger KK., Pannen BH.: Inhibition of AP-1 by barbiturates is mediated by differential effects on MAP-kinases and the small G proteins Ras and Rac-1. *J Pharmacol Exp Ther* 2004; 311:1232-40 (IF: 4.337)
18. **Loop T.**, Scheiermann P., Doviakue D., Musshoff F., Humar M., Roesslein M., Hoetzel A., Schmidt R., Madea B., Geiger KK., Pahl HL., Pannen BH.: Sevoflurane inhibits phorbol-myristate-acetate-induced Activator Protein-1 activation in human T lymphocytes *in vitro*: Potential role of the p38-stress kinase pathway. *Anesthesiology* 2004; 101:710-721 (IF: 3.501)
19. **Loop T.**, Bross T., Humar M., Hoetzel A., Schmidt R., Pahl HL., Geiger KK., Pannen BH.: Dobutamine inhibits phorbol-myristate-acetate (PMA)-induced activation of nuclear factor κ B in human T lymphocytes *in vitro*. *Anesth Analg* 2004; 99:1508-1515 (IF: 2.210)

2005

20. **Loop T.**, Doviakue D., Frick M., Roesslein M., Egger L., Musshoff F., Humar M., Hoetzel A., Schmidt R., Borner C., Geiger KK., Pahl HL., Pannen BH.: Sevoflurane induces mitochondrial- and caspase-3-dependent apoptosis in human T lymphocytes *in vitro*. *Anesthesiology* 2005; 102:1147-1157 (IF: 3.501)

2006

21. Hoetzel A., Leitz D., Schmidt R., Tritschler E., Bauer I., **Loop T.**, Humar M., Geiger KK., Pannen BH.: Mechanism of hepatic heme oxygenase-1 induction by isoflurane. *Anesthesiology* 2006; 104:101-109 (IF: 3.501)
22. Schmidt R., Baechle T., Hoetzel A., **Loop T.**, Humar M., Roesslein M., Geiger KK., Pannen BH.: Dihydralazine treatment limits liver injury after hemorrhagic shock in rats. *Crit Care Med* 2006 34:815-822 (IF: 5.07)

Reviews

23. **Loop T.**, Priebe HJ.: Die arterielle Hypertonie: ihre Bedeutung für die perioperative Morbidität und Mortalität. *Anesthesiol Intensivmed Notfallmed Schmerzther* 1998; 33:292-299 (IF: 0.310)
24. **Loop T.**, Priebe HJ.: Remifentanyl – Einsatz in der ambulanten Anästhesie. *Acta Anaesthesiol Helv* 1999; 1:12-19 (not in JCR)
25. Mols G., **Loop T.**, Geiger K., Farthmann E., Benzing A.: Extracorporeal membrane oxygenation: a ten-year experience. *Am J Surg* 2000;180:144-154 (IF: 2.183)
26. Mols G., **Loop T.**, Hermle G., Buttler J., Huber B., Schubert J., Benzing A.: 10 years experience with extracorporeal membrane oxygenation. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2001; 36:4-14 (IF: 0.310)
27. **Loop T.**: Das Immunsystem: Grundlagen und Modulation durch Anästhetika. *Anästhesiologie und Intensivmedizin* 2003; 44:53-67 (IF: 0.612)
28. **Loop T.**, Pahl HL.: Activators and target genes of Rel/NF- κ B transcription factors - from bench to bedside. In: Beyaert R: Nuclear Factor κ B – Regulation and role in disease. Kluwer Publishing Group, 2003 (book chapter)
29. Pannen B.H.J., **Loop T.**: Evidenzbasierte Intensivtherapie des erhöhten intrakraniellen Drucks nach Schädel-Hirn-Trauma. *Der Anaesthesist* 2005; 54:126-137 (IF: 0.982)

Miscellaneous

30. **Loop T.**, Priebe HJ.: Costs of anaesthesia. *Eur J Anaesthesiol.* 2005;22:162
31. Denschlag D., **Loop T.**, Klisch J., Tempfer C., Anders B., Karck U.: Thrombolytic therapy and combined cesarean section and hysterectomy in prosthetic mitral valve thrombosis in pregnancy. *Acta Obstet Gynecol Scand.* 2005;84:404-6
32. **Loop T.**: *Praxishandbuch Anästhesie – Lungenchirurgie*; Hrsg. Benzing/Pannen, Spitta Verlag, April 2006 (book chapter)